Rheopheresis Blood Filtration Study for the Treatment of Dry Age-Related Macular Degeneration (AMD)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2005 by OccuLogix.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
OccuLogix
ClinicalTrials.gov Identifier:
NCT00078221
First received: February 20, 2004
Last updated: May 8, 2008
Last verified: December 2005

February 20, 2004
May 8, 2008
August 1999
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00078221 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Rheopheresis Blood Filtration Study for the Treatment of Dry Age-Related Macular Degeneration (AMD)
Not Provided

AMD is a progressive disease of the retina which is nourished by a network of tiny blood vessels. There is evidence to suggest that the flow of nutrients to the retina is impaired in patients with AMD. Rheopheresis blood filtration uses blood filters that deplete excesses of large proteins, fats and other substances from the blood, improving blood flow to the macula, potentially improving vision.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Macular Degeneration
Device: Rheopheresis blood filtration
Not Provided
Pulido JS; Multicenter Investigation of Rheopheresis for AMD (MIRA-1) Study Group. Multicenter prospective, randomized, double-masked, placebo-controlled study of Rheopheresis to treat nonexudative age-related macular degeneration: interim analysis. Trans Am Ophthalmol Soc. 2002;100:85-106; discussion 106-7.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
180
December 2005
Not Provided
  • Age 50-85
  • Diagnosis of Dry AMD
  • BCVA between 20/32 and 20/125 in at least one eye
  • Numerous large plaques (soft drusen)
  • No history of HIV, Hepatitis B or C
  • Elevation of certain blood factors, such as total cholesterol, fibrinogen, and IgA
Both
50 Years to 85 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States,   Canada
 
NCT00078221
AMD-02-99
Not Provided
Not Provided
OccuLogix
Not Provided
Study Director: Irving Siegel, MD OccuLogix
OccuLogix
December 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP